Abstract:BackgroundTreatment with rituximab may cause reactivation of hepatitis B virus (HBV).PurposeTo find out if HBV serology for patients with haematological diseases treated with rituximab is routinely performed in accordance with the HBV reactivation prophylaxis protocol. According to the results, to develop a strategy to ensure compliance with the protocol.Material and methodsObservational, retrospective study of haematological patients who started treatment with rituximab between December 2012 and April 2014. T… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.